TRINETRA › Sectors › Healthcare
Sai Life Sciences Limited (SAILIFE) — share price, P/E and fundamentals
Sai Life Sciences Limited (NSE: SAILIFE) closed at ₹1,557.50 on 30 Oct 2026, +78.6% over one year, against a 52-week range of ₹783.85 – ₹1,697.00.
In the quarter ended 30 Jun 2026 (consolidated, filed 6 Aug 2026) it reported revenue of ₹554 cr and net profit of ₹73 cr, a 13.2% net margin; revenue grew 11.7% and profit grew 21.3% year on year.
On four consecutive filed quarters its trailing P/E is 91.4; since 14 May 2025 its own P/E has ranged from 50.9 to 110.5 (median 86.7), and today's reading is higher than 57% of those 362 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 11.8%, ROCE 15.1%, debt-to-equity 0.04, Piotroski F-score 7 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 52% of 63 sector peers; PBT margin higher than 51% of 63 sector peers; ROE higher than 38% of 63 sector peers.
Key figures
| Last close | ₹1,557.50 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -2.3% / +52.0% / +78.6% |
| 52-week low – high | ₹783.85 – ₹1,697.00 |
| Market capitalisation | ₹33,064 cr |
| Trailing P/E | 91.4 |
| Price / book | 13.31 |
| EV / EBITDA | 47.7 |
| Earnings yield | 1.1% |
| TTM EPS | ₹17.04 |
| TTM net profit | ₹362 cr |
| Quarter revenue | ₹554 cr |
| Quarter net profit | ₹73 cr |
| Net margin | 13.2% |
| Revenue growth (YoY) | +11.7% |
| Profit growth (YoY) | +21.3% |
| Return on equity | 11.8% |
| ROCE | 15.1% |
| Debt / equity | 0.04 |
| Current ratio | 1.69 |
| Free cash flow | ₹-84 cr |
| Piotroski F-score | 7 / 9 |
| Average daily turnover (50 days) | ₹64.1 cr |
Against Healthcare peers
| Metric | SAILIFE | Peer median | Percentile |
|---|---|---|---|
| Net margin | 13.22 | 12.67 | 52 |
| PBT margin | 17.68 | 17.57 | 51 |
| ROE | 11.80 | 13.87 | 38 |
| ROCE | 15.13 | 17.26 | 38 |
| Debt / equity | 0.04 | 0.11 | 38 |
| Cash conversion | 1.46 | 1.25 | 69 |
| Trailing P/E | 91.40 | 43.07 | 92 |
| P/B | 13.31 | 5.88 | 85 |
Questions
What is the P/E ratio of Sai Life Sciences Limited?
Sai Life Sciences Limited's trailing P/E is 91.4, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 14 May 2025 its P/E has ranged 50.9–110.5.
What were Sai Life Sciences Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Sai Life Sciences Limited reported revenue of ₹554 cr and net profit of ₹73 cr (consolidated), filed with the exchange on 6 Aug 2026.
What is Sai Life Sciences Limited's ROE?
Return on equity is 11.8% based on the balance sheet dated 31 Mar 2026.
Does Sai Life Sciences Limited have debt?
Debt-to-equity is 0.04 on the balance sheet dated 31 Mar 2026.
What is SAILIFE's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, SAILIFE traded between ₹783.85 and ₹1,697.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.